Chordia Therapeutics Income Statement

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Feb '25 Feb 28, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Revenue	-	-	2,500
Gross Profit	-	-	2,500
Selling, General & Admin	359.66	301.6	291.12
Research & Development	1,628	1,500	1,997
Operating Expenses	1,988	1,801	2,288
Operating Income	-1,988	-1,801	212.06
Currency Exchange Gain (Loss)	-3.09	-3.6	-12.24
Other Non Operating Income (Expenses)	-7.25	-19.71	25.95
Pretax Income	-1,998	-1,825	225.76
Income Tax Expense	2.42	2.42	2.42
Net Income	-2,001	-1,827	223.34
Net Income to Common	-2,001	-1,827	223.34
Shares Outstanding (Basic)	65	59	56
Shares Outstanding (Diluted)	65	59	56
Shares Change (YoY)	-	4.05%	-
EPS (Basic)	-30.96	-31.11	3.96
EPS (Diluted)	-30.96	-31.11	3.96
Free Cash Flow	-2,000	-1,938	543.38
Free Cash Flow Per Share	-30.95	-32.99	9.63
Gross Margin	-	-	100.00%
Operating Margin	-	-	8.48%
Profit Margin	-	-	8.93%
Free Cash Flow Margin	-	-	21.73%
EBITDA	-1,985	-1,797	218.1
EBITDA Margin	-	-	8.72%
D&A For EBITDA	3.21	4.09	6.04
EBIT	-1,988	-1,801	212.06
EBIT Margin	-	-	8.48%
Effective Tax Rate	-	-	1.07%

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.